Trials / Completed
CompletedNCT00599443
Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years
Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
A controlled, double blinded study to determine the safety and reactogenicity in healthy adults of a single dose of a trivalent cell-derived influenza vaccine administered by intramuscular injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Seasonal cell-derived influenza vaccine | 0.5 mL im, single dose |
| BIOLOGICAL | Placebo Comparator | 0.5 mL im, single dose |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2008-01-23
- Last updated
- 2008-06-30
Source: ClinicalTrials.gov record NCT00599443. Inclusion in this directory is not an endorsement.